• SHARE

Moderna Inc.’s highly effective COVID-19 vaccine, in addition to protecting millions, is officially a cash cow.

The company disclosed during its earnings presentation Aug. 5 that it expects the shot to generate $20 billion in sales this year. Now it has to figure out what to do with its windfall as it tries to justify a market valuation that has surged by more than $100 billion since May. That’s a nice problem to have. But it’s also an urgent strategic issue.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)